GlaxoSmithKline (GSK) is a global pharmaceutical company incorporated in 2000 by the merger of Glaxo Wellcome and SmithKline Beecham and has its headquarters in Brentford, UK.
GSK’s revenue of $34.928 billion, R & D expenditure of $5.198 billion and a basic EPS of $1.06, in 2015, have made it the 6th top pharmaceutical company in the world In 2015. GSK operates in three business segments, namely, Pharmaceuticals, Vaccines and Consumer Healthcare.
Each business segment contributing to 59.2%, 15.3% and 25.2%, respectively of the annual revenue 2015. Pharmaceuticals segment comprises of Global Pharmaceuticals with drugs for respiratory, cardiovascular, metabolic and urology, oncology and immuno-inflammation-related illnesses and the HIV Pharmaceuticals which has drugs like Triumeq and Epzicom. Vaccines segment had major revenues from vaccines for Hepatitis and vaccines like Rotarix and Infanrix. Consumer Healthcare segment provides wellness, oral health, skin health and nutrition solutions with major brands like Horlicks, Sensodyne and Eno under its umbrella. The Consumer Healthcare segment represents the Joint Venture with Novartis Consumer Healthcare division and with other related-companies in India and Nigeria.
GSK is featured in the Fortune Global 500 Companies list with rank as 309. GSK would release the drug, Strimvelis for the treatment of Bubble boy disease, a genetic disorder, fatal in untreated children after approval from the European Commission, which shows its commitment to bring-to-the-market, innovative and need-of-the-hour healthcare solutions.